MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets

Qi, Ling‐Yu; Gao, Chundi; Feng, Fubin; Zhang, Tingting; Yao, Yan; Wang, Xue; Liu, Cun; Li, Jia; Li, Jie; Sun, Changgang

doi:10.1002/jcb.29216

Cited by 38 publications

(30 citation statements)

References 71 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs have been described as promising therapeutic targets in cancers [119,120]. Poudyal et al demonstrated that miRNA-6852 overexpression could induce G2/M phase arrest in cervical cancer cells [121].…”

Section: Potential Clinical Application Of Regulatory Mechanisms Betwmentioning

confidence: 99%

The interplay between m6A RNA methylation and noncoding RNA in cancer

et al. 2019

View full text Add to dashboard Cite

N6-methyladenosine (m6A) methylation, one of the most common RNA modifications, has been reported to execute important functions that affect normal life activities and diseases. Most studies have suggested that m6A modification can affect the complexity of cancer progression by regulating biological functions related to cancer. M6A modification of noncoding RNAs regulates the cleavage, transport, stability, and degradation of noncoding RNAs themselves. It also regulates cell proliferation and metastasis, stem cell differentiation, and homeostasis in cancer by affecting the biological function of cells. Interestingly, noncoding RNAs also play significant roles in regulating these m6A modifications. Additionally, it is becoming increasingly clear that m6A and noncoding RNAs potentially contribute to the clinical application of cancer treatment. In this review, we summarize the effect of the interactions between m6A modifications and noncoding RNAs on the biological functions involved in cancer progression. In particular, we discuss the role of m6A and noncoding RNAs as possible potential biomarkers and therapeutic targets in the treatment of cancers.

show abstract

Section: Potential Clinical Application Of Regulatory Mechanisms Betwmentioning

confidence: 99%

The interplay between m6A RNA methylation and noncoding RNA in cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Current prognostic biomarkers for LUSC included prognostic alternative mRNA splicing signature, lncRNA signatures, and microRNA signatures [9,[11][12][13]. However, these studies [9,[11][12][13] only included LUSC data from the TCGA database. In this study, we built IRGPI based on 13 immune-related gene pairs from the training cohort and explored the prognostic value of IRGPI in the testing and validation cohorts.…”

Section: Discussionmentioning

confidence: 99%

“…Hu et al constructed a 3-lncRNA signature for LUSC and the AUC of this model associated with 3-year survival was 0.629 in the training cohort [12]. Qi et al identi ed 12 miRNAs closely related to the overall survival of patients with LUSC [13]. Yang et al identi ed the diagnostic role of miRNA-486-5p in the TCGA LUSC cohort [25].…”

Section: Comparison Of Biomarkers For Luscmentioning

confidence: 99%

“…Previous studies associated with prognosis of lung squamous cell carcinoma (LUSC) patients mainly concentrated on the alternative mRNA splicing signatures, lncRNA signatures, and other transcriptome signatures [8][9][10][11][12][13]. As the component of the tumor microenvironment, tumor-in ltrating immune cells (TIICs) revealed promising value for providing prognostic biomarkers [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of an Immune-Related Gene Pair Index as a Prognostic Marker of Lung Squamous Cell Carcinoma

Wang

Xuan

Wei

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: Lung squamous cell carcinoma (LUSC) is one of the subtypes of non-small-cell lung cancer (NSCLC) and accounts for approximately 20 to 30% of all lung cancers. Methods: In this study, we developed an immune-related gene pair index (IRGPI) for LUSC from 8 public LUSC data sets, including The Cancer Genome Atlas LUSC cohort and Gene Expression Omnibus data sets, and explored the prognostic value of IRGPI for patients with LUSC. Results: IRGPI was constructed by 13 gene pairs consisting of 25 unique immune-related genes from the training cohort. Multivariate cox regression analysis showed that high risk based on IRGPI was an independent risk factor for poor prognosis of patients with LUSC in the training cohort (230 patients; HR= 3.40; 95%CI [2.34-4.94]; p<0.001), the testing cohort (228 patients; HR=2.11; 95%CI [1.48-3.01]; p<0.001) and the validation cohort (472 patients; HR=1.99; 95%CI [1.5-2.63]; p<0.001). The infiltrations of naïve B cells, plasma cells, CD8+ T cells, activated memory CD4+ T cells, gamma delta (γδ) T cells, M1 macrophages, and activated dendritic cells were lower in the high-risk group, as compared with the low-risk group in the TCGA cohort. The infiltrations of neutrophils, activated mast cells, and monocytes were higher in the high-risk group. Conclusions: IRGPI is a significant prognostic biomarker for predicting overall survival in LUSC patients. Combining clinical features with IRGPI will improve prognostic accuracy.

show abstract

“…Previous studies associated with prognosis of LUSC patients mainly concentrated on the alternative mRNA splicing signatures, lncRNA signatures, and other transcriptome signatures [8][9][10][11][12][13]. As the component of the tumor microenvironment, tumor-in ltrating lymphocytes (TIL) revealed promising value for providing prognostic biomarkers [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Validation of an Immune-related Gene Pair Index as a Prognostic Marker of Early-Stage Lung Squamous Cell Carcinoma

Wang¹,

Xuan²,

Wei³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Lung squamous cell carcinoma (LUSC) is one of the subtypes of non-small-cell lung cancer (NSCLC) and accounts for approximately 20 to 30% of all lung cancers.Methods. In this study, we developed an immune-related gene pair index (IRGPI) for early-stage LUSC from 3 public LUSC data sets, including The Cancer Genome Atlas LUSC cohort and Gene Expression Omnibus data sets, and explored whether IRGPI could act as a prognostic marker to identify patients with early-stage LUSC at high risk.Results. IRGPI was constructed by 68 gene pairs consisting of 123 unique immune-related genes from TCGA LUSC cohort. In the derivation cohort, the hazard of death among high-risk group was 10.51 times that of the low-risk group (HR, 10.51; 95%CI, 6.96-15.86; p<0.001). The hazard of death among the high-risk group was 2.26 times that of the low-risk group (HR, 2.26; 95%CI, 1.2-4.25; p=0.009) in the GSE37745 validation cohort and was 3.2 times that of low-risk group (HR, 3.2; 95%CI, 0.98-10.4; p=0.042) in the GSE41271 validation cohort. The infiltrations of CD8+ T cells and T follicular helper cells were lower in the high-risk group, as compared with the low-risk group in the TCGA cohort (6.94% vs 9.63%, p=0.004; 2.15% vs 3%, p=0.002, respectively). The infiltrations of neutrophils, activated mast cells and monocytes were higher in the high-risk group, as compared with the low-risk group in the TCGA cohort (1.63% vs 0.72%, p=0.001; 1.64% vs 1.02%, p=0.007; 0.57% vs 0.35%, p=0.041, respectively).Conclusions. IRGPI is a significant prognostic biomarker for predicting overall survival in early-stage LUSC patients.

show abstract

MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets

Cited by 38 publications

References 71 publications

The interplay between m6A RNA methylation and noncoding RNA in cancer

The interplay between m6A RNA methylation and noncoding RNA in cancer

Validation of an Immune-Related Gene Pair Index as a Prognostic Marker of Lung Squamous Cell Carcinoma

Validation of an Immune-related Gene Pair Index as a Prognostic Marker of Early-Stage Lung Squamous Cell Carcinoma

Contact Info

Product

Resources

About